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Coronary Heart Disease (CHD) remains a leading cause of UK mortality, generating a large
and unequal burden of disease. Dietary trans fatty acids (TFA) represent a powerful CHD
risk factor, yet to be addressed in the UK (approximately 1% daily energy) as successfully
as in other nations. Potential outcomes of such measures, including effects upon health
inequalities, have not been well quantified. We modelled the potential effects of specific
reductions in TFA intake on CHDmortality, CHD related admissions, and effects upon
socioeconomic inequalities.
Methods & Results
We extended the previously validated IMPACTsecmodel, to estimate the potential effects
of reductions (0.5% & 1% reductions in daily energy) in TFA intake in England and Wales,
stratified by age, sex and socioeconomic circumstances. We estimated reductions in
expected CHD deaths in 2030 attributable to these two specific reductions. Output mea-
sures were deaths prevented or postponed, life years gained and hospital admissions. A
1% reduction in TFA intake energy intake would generate approximately 3,900 (95% confi-
dence interval (CI) 3,300–4,500) fewer deaths, 10,000 (8,800–10,300) (7% total) fewer hos-
pital admissions and 37,000 (30,100–44,700) life years gained. This would also reduce
health inequalities, preventing five times as many deaths and gaining six times as many life
years in the most deprived quintile compared with the most affluent. A more modest reduc-
tion (0.5%) would still yield substantial health gains.
Conclusions
Reducing intake of industrial TFA could substantially decrease CHDmortality and hospital
admissions, and gain tens of thousands of life years. Crucially, this policy could also reduce
health inequalities. UK strategies should therefore aim to minimise industrial TFA intake.
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Introduction
Coronary Heart Disease (CHD) continues to be a leading cause of mortality and morbidity in
the UK. Despite halving of (CHD) mortality rates over the past two decades [1] approximately
35% of total UK deaths are still attributable to Cardiovascular Disease (CVD). Coupled with
the chronic disease burden, especially in the older age groups [2], this is estimated to cost the
economy £30 billion every year [3] with some £14 billion spent annually on healthcare alone.
Major behavioural risk factors for CHD are diet and smoking, followed by excess alcohol con-
sumption and physical inactivity [4]. Within diet the key factors include low intakes of fruit
and vegetables, and wholefoods, and an excess intake of salt, sugar, saturated fats, and trans
fatty acids (TFA).
TFA consumption comprises industrial TFA (approximately 1% daily energy intake), and
ruminant TFA (approximately 0.5% daily energy intake). Industrial trans fats are unsaturated
fatty acids with at least one double bond in the trans configuration, formed during the partial
hydrogenation of vegetable oils. This process is utilised in the production of margarines, com-
mercial cooking and manufacturing processes. The partial hydrogenation process provides a
solid fat with longer shelf life, stability during packing, and enhanced palatability. The major
sources of TFA in the UK are bakery products, spreads, packaged snack foods and deep-fried
fast foods. Naturally occurring TFA, such as in meats, dairy and other ruminant products are
produced by the action of bacteria in the ruminant stomach, and account for approximately
0.5% of total energy intake in the UK population. The role of ruminant TFA upon CHD risk is
much less well characterised than industrial TFA, and as a recent review has highlighted [5],
this topic remains debated, particularly by the dairy industry. Whilst the harmful effect of
ruminant TFA was thought to be relatively minor in the past, there is a growing argument that
their CHD risk may have been underestimated because of their relatively low intake levels [5].
Industrial TFA substantially increase CHD risk by raising LDL-cholesterol, reducing HDL-
cholesterol, causing systemic inflammation and adversely affecting endothelial cell dysfunction
[6]. On a per calorie basis, TFA increase CHD risk more than any other macronutrient [6] as
every 1% increase in daily energy obtained from TFA raises CHD mortality by 12% [6]: CVD
(primary) prevention policies, highlighting reductions in TFA, are therefore gaining more
attention and traction. In developed countries, the average daily TFA intake has fallen over the
past decade reaching approximately 1.3% (2.8grammes) of daily energy intake in the UK [7].
This fall can be attributed to pressure from UK Foods Standard Agency (FSA) 2003–2007
reformulation efforts, and voluntary content labelling globally [8]. However, this purely volun-
tary approach appears to be becoming exhausted as the rate of reduction has recently (from
2007–2011) slowed [9]. Yet even such apparently low average levels of TFA have dangerous
consequences and increase CHD risk substantially, particularly in deprived groups consuming
higher amounts of TFA [10].
Several effective policies have been utilised to successfully reduce dietary TFA across the
globe, including voluntary self regulation, content labelling, or local or national legislation [11].
New York City led the US through reduction in TFA in restaurant food and voluntary self reg-
ulation; this has seen population TFA levels halve in the USA [9]. However, due to incomplete
population coverage, this approach allows residual pockets of the population to have a persis-
tently high TFA intake [11] due to more deprived communities tending to purchase more pro-
cessed products which provide the ‘cheap’ calories and meals. National legislative bans, such as
seen in Demark, Iceland, Austria and Switzerland have been the most effective policies, essen-
tially eliminating industrial TFA in foods [12]. Achieving the lowest possible TFA level is there-
fore of great importance. There is no room for complacency, and considerable scope remains
to develop further policies to continue this reduction within the UK population.
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Furthermore, UK health inequalities in socio-economic circumstances (SEC) remain sub-
stantial [13]. Thus, despite the one third reduction in CHDmortality between 1980–2007,
large inequalities have persisted, and even worsened in some age groups [14]. Treatment
uptake appears surprisingly equitable across SEC quintiles [15] clearly suggesting that much of
the persistent CHD inequality must be attributable to differences in major cardiovascular risk
factors [16]. However, in order to implement more effective prevention policies in the future,
UK policy makers will require solid evidence to assess and quantify the potential benefits in
tackling CHD inequalities achievable through population level reductions of TFA.
We therefore aimed to quantify the potential benefits of population level reductions in TFA
consumption in the UK. Further, we aimed to quantify the effects upon inequalities in mortal-
ity, life years and hospital admissions, in order to help inform future prevention strategies.
Methods
Data Sources for the IMPACT CHDModel
We extended the current and validated IMPACTSEC CHDmodel calibrated for the English and
Welsh population to estimate the effect of different population level reductions in TFA on
mortality, life-years, and the underlying CHD burden. We named this IMPACTTFA model.
The population was stratified by age (10 year age groups from 25–34 up to 85+), gender and
SEC (quintiles based on Index of Multiple Deprivation (IMD) scores). The Index of Multiple
Deprivation (IMD) is a composite index of relative deprivation at small area level based on
seven domains: income; employment; health deprivation and disability; education, skills and
training; barriers to housing and services; crime and disorder; and living environment [17].
The age groups were then further categorised to analyse trends in young, middle aged, and
elderly (less than 55 years, 55 to 74 years, and 75 years old). Mortality and demographic data
for the IMPACTSEC model were obtained from the Office of National Statistics. Patient num-
bers were estimated for seven mutually exclusive patient groups (Acute Myocardial Infarction
(AMI), unstable angina (UA), secondary prevention post AMI, secondary prevention post
revascularisation, angina in the community, heart failure admissions, heart failure in the com-
munity) using data from Hospital Episodes Statistics, Myocardial Ischaemia National Audit
Project and General Practice Research Database. For the TFA model we only included inci-
dence patient numbers, ie AMI, UA and heart failure admissions due to insufficient data
regarding TFA affect upon case fatality. The mortality reduction for a given reduction in TFA
was taken from the systematic review by Mozaffarian (2006) [6], whilst this effect was stratified
into age and sex specific reductions in mortality by O’Flaherty et al [10], assuming that they are
consistent with the age and gender coronary heart disease mortality effects gradients observed
with cholesterol changes [18]. Upper and lower estimates for the probabilistic sensitivity analy-
sis were generated using 80% and 120% of the mean estimates respectively. This effect size is
for total effect of TFA upon CHDmortality, rather than through cholesterol effects alone. The
effect gradient across these groups was conserved to create mortality reduction factors for
given levels of reductions in TFA intake resulting in TFA intake of 0.5% and 0% of daily energy
intake respectively. Stratifications, by age and gender, of mortality reduction factors, for a 1%
reduction, and 0.5% reduction in trans fats intake (as a percentage of daily energy intake) are
available in table B in S1 File. As no data was available from this systematic review among the
oldest age group (85), a mortality reduction was calculated by extrapolation from the younger
age groups and tested in a probabilistic sensitivity analysis. The mortality reduction among
those 85 was extrapolated by assuming that the same attenuation of the relative risk would
occur with age as has been found for the relationship between total cholesterol and CHDmor-
tality risk by age.
Quantifying the Socio-Economic Benefits of Reducing Trans Fat
PLOS ONE | DOI:10.1371/journal.pone.0132524 August 6, 2015 3 / 16
IMPACTTFA Model Methods. The expected number of deaths in 2016, 2020 and 2030
were calculated by using a Bayesian Age-period-cohort model based forecast [19]. To estimate
the effect of changes in TFA intake, we calculated the number of expected deaths from CHD
occurring at each time point (2016, 2020 and 2030) first with no change in trans fats intake and
second assuming a certain reduction in TFA intake in the corresponding year (2016, 2020 and
2030). Using the mortality reduction values for given levels of TFA reduction as described
above assuming a linear dose-response relationship between TFA intake and CHD risk, this
provided the deaths prevented or postponed (DPPs) for men and women in each age and
socio-economic circumstance quintile.
Using the calculated DPPs, we then estimated the number of life-years gained by multiply-
ing the deaths prevented or postponed for the specific reduction in TFA by the age specific
median survival for the different population subgroups (diagnosed CHD, undiagnosed CHD
and population free of CHD). Estimates of median survival for these subgroups were initially
obtained from a previous analysis performed for the England and Wales population for 2000
[20–23], and was updated with more recent (2010) data adapted from Smolina et al [24]. Here,
median survival data was obtained from the best available population-based data for those
patients with recognised CHD, symptomatic but unrecognised CHD, and asymptomatic indi-
viduals. We used probabilistic sensitivity analysis for parameter uncertainty. This was done
using Monte Carlo simulation, involving repeating the estimation of the model, drawing
parameter values from their respective statistical distributions. The distributions and sources of
each input into the sensitivity analysis are outlined in table A in S1 File. We then used the
Microsoft Excel add-in program Ersatz software to perform 5,000 simulations to determine the
95% confidence intervals of the DPPs (2.5th and 97.5th percentile values corresponding to
lower and upper limits). For simplicity, rounded ‘best estimates’ and precise confidence inter-
vals are included in the text, whilst precise values are presented in the subsequent tables and
figures. The lower and upper confidence intervals are derived from 5% and 95% centiles of
10,000 Monte Carlo simulations. Since many input variables are not normally distributed the
confidence intervals may not be symmetrical.
The resulting effect of given reductions in TFA upon the CHD burden was derived from the
incidence patient numbers. This included hospital admissions for acute myocardial infarction,
unstable angina and heart failure and excluded community prevalence numbers of angina,
heart failure and myocardial survivors living in the community. This was due to an assumed
negligible effect of this policy upon case fatality itself, hence limited effect upon underlying
community prevalence. The resulting number of patients were derived from the mortality
reduction percentage and existing incidence numbers by disease group. The relative distribu-
tion and ratios of patients across the disease groups within the underlying burden remained
constant from the initial patient numbers to the resultant.
Socio-economic circumstance analysis
The SEC component of the IMPACT model used the Index of Multiple Deprivation (IMD) as
previously described [14]. This is a widely used measure in the UK of relative area deprivation
based on seven domains: income; employment; health deprivation and disability; education;
skills and training; barriers to housing and services; crime and disorder; and living environ-
ment [17]. To model the effects of given reductions in TFAs upon the health inequalities within
the CHD burden, we modelled two different scenarios. Firstly, a conservative model, which
assumed equal TFA intake as a percentage of daily energy intake across SECs, named TFAsec1.
Secondly, a model assuming an unequal intake of TFA as a percentage of daily energy intake
across SEC quintiles (table B in S1 File), named TFAsec2. No adjustment for total daily energy
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intake by SEC was made. These models stratified the data by socio-economic circumstance in
the following ways:
1. The UK coronary heart disease population are stratified into SEC IMD quintile populations
2. SEC quintile specific mortality counterfactuals
3. SEC quintile specific median survivals
4. SEC quintile specific intake of TFA in TFAsec2
SEC specific mortality counterfactuals were calculated for the year 2030, whilst median sur-
vival for the ‘undiagnosed CHD’ and ‘no CHD’ groups were stratified by SEC. This was done
using life expectancies by SEC IMD quintiles from 2007–10 [25] and creating indices of life
expectancy where SEC quintile three was the index, 1.0. The respective index for each SEC
quintile was then used to calculate a more specific median survival by SEC. In the case of the
‘undiagnosed CHD’ group, median survival was taken as the midpoint between the ‘diagnosed
CHD’ and ‘no CHD’ groups. The mean TFA intake across the UK population was taken from
the Low Income Diet and Nutrition Survey [7] (1.3%) whilst tailored trans fats intake by SEC
quintile was adapted from this survey. This is outlined in table B in S1 file.
In TFAsec1, whereby TFA intake is assumed to be equal across SEC quintiles, the results are
additionally presented as an index, using socio-economic circumstance quintile 3 as the index
1.0. Further, these indices are calculated using percentages, with the denominator being the
specific UK population for that SEC quintile, age and sex group. This was done to use rates,
rather than crude numbers to avoid misleading results due to the large differences in crude
population numbers across SEC quintiles in the older age groups, owing to variation in their
respective life expectancies.
Results
Effects of a reduction in trans fatty acids intake by 1% and 0.5% (as % of
daily energy intake) on deaths prevented or postponed, life years gained
and Hospital Admissions
Deaths Prevented or Postponed. A 1% reduction in TFA of daily energy intake across the
England and Wales population would result in approximately 3,900 (95% confidence interval
(CI) 3,325–4,453) DPPs per year. Over half (60%, n = 2400) of these deaths prevented would
be among men, with the remainder (n = 1500) among women; and most among people over 75
years old. (Table 1, Fig 1)
A 0.5% reduction in TFA of daily energy intake would result in approximately 1900 (95%
CI: 1,660–2,228) deaths prevented or postponed per year. (Fig 1)
Life Years Gained. A 1% reduction in TFA of daily energy intake across the England and
Wales population would result in some 37,000 (95% CI: 30,106–44,670) LYGs per year. About
20,000 of these would be among men, and 20,000 among women). Although most LYGs would
be among the elderly (people over 75), some 25% would be among younger people (under 55
years). (Table 1, Fig 2)
A 0.5% reduction in TFA of daily energy intake would result in approximately 19,000 (95%
CI: 15,039–22,309) LYGs per year. (Fig 2)
Hospital Admissions. A 1% energy reduction in TFA intake would result in approxi-
mately 9,800 (95% CI: 8,783–10,258) fewer CHD related hospital admissions than in 2007.
This total comprises some 1,500 (95% CI: 1,321–1,761) fewer acute myocardial infarction
admissions, approximately 1,500 (95% CI: 1,325–1,766) fewer heart failure (HF) admissions,
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and some 6,700 (95% CI: 6,139–6,731) fewer unstable angina hospital admissions. This repre-
sents a 7% reduction in CHD related hospital admissions. The reductions seen in male hospital
admissions (6,000) was greater than for females (4,000), with middle aged men (55–75 years
old) seeing the largest potential reductions in unstable angina and acute myocardial infarction
Table 1. The effects, per year, upon the UK population of a reduction from 1% to 0% in trans fatty acids of daily energy intake. Numbers of Deaths
prevented or postponed (DPP), life years gained (LYG), Reductions in Acute Myocardial Infarction (AMI) Admissions, Reductions in Unstable Angina (UA)
Admissions and reductions in Heart Failure (HF) admissions. Stratified by age and gender. Reduction in TFA intake by 0.5% daily energy yield half of the
below gains.
TFA Age
1% reduction Totals 95% CI 95% CI <55 55–75 >75
DPP 3900 3325 4453
Men 2400 265 625 1471
Women 1500 64 203 1257
LYG 37000 30106 44670
Men 20000 6721 7012 6014
Women 17000 2381 4198 10718
AMI admissions reductions 1500 1320 1761
Men 1000 359 431 237
Women 500 82 169 263
Unstable Angina admissions reductions 6800 5865 7828
Men 4100 1442 1807 823
Women 2600 564 972 1102
Heart Failure admissions reductions 1500 1325 1766
Men 800 90 290 430
Women 700 46 166 523
The lower and upper conﬁdence intervals are derived from 5% and 95% centiles of 10,000 Monte Carlo simulations. Since many input variables are not
normally distributed the CI may not be symmetrical. All ﬁgures above are per annum. Totals are rounded.
doi:10.1371/journal.pone.0132524.t001
Fig 1. Deaths prevented or postponed (DPPs) per year with a 1% and 0.5% reduction in daily energy
intake of trans fatty acids intake. DPPs by age and sex. Data source: Hospital Episode Statistics.
doi:10.1371/journal.pone.0132524.g001
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admissions. Heart Failure admissions however were reduced most in the oldest age groups
(over 75 years). (Table 1, Fig 3)
A small reduction in TFA intake of 0.5% energy would still result in significant health gains.
Namely approximately 4,900 (95% CI: 4,256–5,682) fewer CHD related hospital admissions
than in 2007. This comprises approximately 750 (95% CI: 660–881) fewer acute myocardial
infarction admissions, 750 (95% CI: 663–883) fewer heart failure admissions and 3,400 (95%
CI: 2,933–3,917) fewer unstable angina admissions. (Fig A in S1 File)
The effect upon Coronary Heart Disease socio-economic inequalities
Assuming equal intake of trans fatty acids across socio-economic circumstance quin-
tiles. A 1% reduction in TFA intake across all SEC quintiles, conservatively assuming equal
intake across SEC quintiles would result in approximately 33% more DPPs in the most
deprived quintile than the most affluent. Further, this would also lead to approximately 12,000
(95% CI: 7,447–16,756)LYGs in the most deprived quintile, compared to some 4,000 (95% CI
2,723–6,126) LYGs in the most affluent quintile (Table 2), whilst a 60% greater reduction in
hospital admissions would be seen in the most deprived compared with the most affluent
group. (Table 3, Fig 3)
Modelling unequal intake of trans fatty acids across socio-economic circumstance quin-
tiles. Reducing dietary TFA intake to 0.5% of daily energy intake (ie eliminating industrial
trans fats intake) throughout all SEC groups, would result in approximately 2,400 (95% CI:
1,934–2,901) deaths prevented or postponed (Fig 4), some 28,000 (95% CI: 19,937–37,224) life
years gained (Fig 5) and approximately 6,000 (95% CI: 4,808–7,212) fewer hospital admissions.
The latter would comprise some 2,300 (95% CI: 1,807–2,711) fewer acute myocardial infarction
admissions, approximately 2,800 (95% CI: 2,259–3,389) fewer unstable angina admissions and
Fig 2. Life years gained (LYG) per year with a 1% and 0.5% reduction in daily energy intake of trans fatty acids. Life years gained (LYG) by age and
sex. Data source: Hospital Episode Statistics.
doi:10.1371/journal.pone.0132524.g002
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Fig 3. Hospital Admissions of Acute Myocardial Infarction (AMI), Unstable Angina (UA) and Heart Failure (HF) per year with a 1% reduction in daily
energy intake of trans fatty acids intake. 4a Male, 4b Female. Hospital admissions by age. Data source: Hospital Episode Statistics.
doi:10.1371/journal.pone.0132524.g003
Table 2. The effects, per year, upon the UK population of a reduction from 1% to 0% trans fatty acids of daily energy intake across all socio-eco-
nomic circumstance quintiles. Numbers of Deaths prevented or postponed (DPP), life years gained (LYG), Reductions in Acute Myocardial Infarction (AMI)
Admissions, Reductions in Unstable Angina (UA) Admissions and reductions in Heart Failure (HF) admissions. Stratified by gender and socio-economic cir-
cumstance (SEC) quintile. 0.5% reduction in TFA intake yields half below gains.
TFAsec
1% reduction Totals 95% CI 95% CI SEC1 SEC2 SEC3 SEC4 SEC5 Total
DPP 4000 3232 4849
Men 2500 413 475 503 512 556 2458
Women 1600 261 307 329 340 345 1582
LYG 43000 27246 61303
Men 21700 1180 4206 4669 5198 6439 21691
Women 21400 3258 3825 4283 4708 5282 21357
AMI admissions reductions 3900 3082 4623
Men 2600 448 501 529 531 560 2570
Women 1300 209 247 255 274 298 1283
Unstable Angina admissions reductions 4500 3629 5443
Men 2700 396 457 518 577 718 2666
Women 1900 256 322 356 418 517 1869
Heart Failure admissions reductions 2200 1790 2685
Men 600 80 102 121 140 189 631
Women 1600 269 318 334 338 347 1607
doi:10.1371/journal.pone.0132524.t002
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Table 3. The effects, per year, upon the UK population of reducing trans fatty acids intake by 1% of daily energy intake across all socio-economic
circumstance quintiles. Numbers of Deaths prevented or postponed (DPP), life years gained (LYG), Reductions in Acute Myocardial Infarction (AMI)
Admissions, Reductions in Unstable Angina (UA) Admissions and reductions in Heart Failure (HF) admissions. Stratified by gender and socio-economic cir-
cumstance (SEC) quintile.
TFAsec <55yrs
1% reduction Totals SEC1 SEC2 SEC3 SEC4 SEC5 Total
DPP 400
Men 300 34 41 53 71 108 308
Women 100 8 10 13 21 34 86
LYG 12000
Men 8000 524 1198 1549 2046 3030 8348
Women 4000 365 435 553 903 1375 3631
AMI admissions reductions 1100
Men 900 130 146 179 198 244 898
Women 200 22 30 33 50 69 204
Unstable Angina admissions reductions 1300
Men 900 107 123 163 209 301 903
Women 400 40 59 69 106 169 442
Heart Failure admissions reductions 700
Men 100 11 12 16 20 31 90
Women 600 85 105 114 122 136 562
55-74yrs
1% reduction Totals SEC1 SEC2 SEC3 SEC4 SEC5 Total
DPP 900
Men 700 96 120 132 145 181 674
Women 200 28 34 43 51 66 222
LYG 11400
Men 6700 269 1372 1478 1585 1952 6656
Women 4700 611 736 937 1094 1364 4742
AMI admissions reductions 1500
Men 1100 197 226 219 220 215 1078
Women 400 65 79 84 87 106 422
Unstable Angina admissions reductions 1900
Men 1200 176 213 227 248 297 1161
Women 700 98 123 141 157 200 719
Heart Failure admissions reductions 800
Men 200 23 31 37 43 60 194
Women 600 104 122 128 127 129 610
_>75yrs
1% reduction Totals SEC1 SEC2 SEC3 SEC4 SEC5 Total
DPP 2800
Men 1500 283 314 317 296 266 1477
Women 1300 225 263 274 268 246 1275
LYG 15900
Men 5100 281 1299 1293 1205 1061 5140
Women 10700 1926 2234 2323 2223 2028 10734
AMI admissions reductions 800
Men 600 121 129 131 113 100 594
Women 200 22 30 33 50 69 204
Unstable Angina admissions reductions 1300
(Continued)
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some 900 (95% CI: 742–1,113) fewer heart failure admissions. This models a baseline of
unequal intake of TFA across SEC quintiles. (Fig B in S1 File)
Furthermore, reducing TFA energy intake to 0.5% across all quintiles would result in a five-
fold or even six fold greater gains in the most deprived compared with the most affluent quin-
tiles in terms of DPPs, LYGs and hospital admissions avoided (Fig B in S1 File)
Discussion
Reducing industrial TFA intake in the UK could substantially decrease CHDmortality and
hospital admissions whilst gaining tens of thousands of life years. Whilst mortality reductions
would be observed primarily in the older age groups, middle aged males would see the greatest
reductions in hospital admissions and a significant minority of life years gained would occur
among younger people.
Socioeconomic Circumstances
Reducing TFA intake could also substantially reduce existing health inequalities in CHD [14].
The conservative model, assuming a consistent 1% reduction in TFA intake across all SEC
quintiles demonstrated a third more deaths prevented, and a two thirds greater reduction in
hospital admissions in the most deprived quintile compared with the most affluent.
However the Low Income Diet and Nutrition Survey (LIDNS) UK survey data [7] demon-
strates a very unequal consumption of TFA across SEC quintiles, with the most deprived
groups having much higher intake of ‘cheap calories’ such as processed foods and ‘takeaways’.
Modelling this unequal intake across SEC quintiles, (assuming a greater fall from higher start-
ing levels in the most deprived groups) (quintile 1–0.75%, quintile 2–0.87%, quintile 3–1%,
quintile 4–1.25%, quintile 5–1.5%) in line with LIDNS data suggested even greater potential
reductions of the CHD inequalities.
A legislative ban eliminating industrial TFA, as has been achieved in other European coun-
tries such as Denmark, would achieve a TFA reduction averaging approximately 0.5% of daily
energy intake across all SEC quintiles. This scenario could result in approximately 2,400 fewer
deaths, 6,000 fewer hospital admissions and 28,000 LYGs.
Treatment uptake for CHD has been shown to be surprisingly equitable across all socio-eco-
nomic circumstance quintiles [15], however large SEC gradients in hospital admissions and
community prevalence of CHD persist. This suggests that population wide changes in CHD
risk factors, which are unequal across SEC quintiles, represent an underutilised tool to address
health inequalities in CHD. Our model suggests that population level primary prevention
achieving a universal reduction in TFA intake could generate benefits five or six-fold greater in
the most deprived quintiles, thus resulting in large reductions in CHD inequalities.
CHDmortality rates fell by approximately 35% between 1999–2007, whilst the overall bur-
den of CHD encompassing hospital incidence and community prevalence fell from 1.9million
Table 3. (Continued)
Men 600 113 121 128 120 120 603
Women 700 118 141 146 155 148 709
Heart Failure admissions reductions 800
Men 300 46 59 68 76 98 347
Women 400 80 91 92 89 83 435
All ﬁgures above are per annum. Totals are rounded.
doi:10.1371/journal.pone.0132524.t003
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in 1999 to 1.7 million in 2007 [14]. However, SEC inequalities persisted and even worsened in
some age groups during this period. This highlights the inadequacy of previous prevention pol-
icies. The case for more effective policies in reducing CHD inequalities has therefore never
been stronger. Furthermore, diabetes and obesity, two significant risk factors for CHD, both of
which are affected by the intake of TFAtrans fats worsened across all SEC quintiles, but partic-
ularly in the most deprived [26].
Fig 4. Deaths prevented or postponed (DPPs) Index with a 1% reduction in daily energy intake of trans fatty acids intake.DPPs by age, gender and
socio-economic circumstance assuming equal TF intake. Data source: Hospital Episode Statistics.
doi:10.1371/journal.pone.0132524.g004
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Other European countries have utilised effective and powerful population-wide policies, to
achieve substantial reductions in tobacco, dietary salt, saturated fats, sugars and trans fats.
Namely, effective bans on industrial TFA has been achieved in Denmark, Iceland, Sweden and
Switzerland, whilst TFA have not been classified ‘Generally Recognised As Safe’ (GRAS) by the
FDA, paving the way for future regulation. Such policies have resulted in large and rapid reduc-
tions in cardiovascular mortality and morbidity. [27–29]
Our results are reassuringly consistent with previous studies. Mozaffarian et al [30] analysed
TFA consumption in Iran, and the effects upon CHD. Baseline intake of TFA was 5–6 times
above effective industrial TFA elimination ie 0.5% daily energy intake, than in the UK, whilst
baseline mortality rates were also higher. This study suggested that elimination of industrial
TFA could prevent 5,600–27,300 CHD deaths. Similarly, Danaei et al [31] suggested that
approximately 82,000 CHD events (not deaths) could be prevented if TFA were eliminated in
the USA. This study used 2005 TFA intake (2.6% of daily energy) data as baseline, hence our
study uses considerably more recent (lower) TFA intake data, giving more modest, albeit still
highly significant health benefits. These modelling results are consistent with the significant
(50%) reductions in CHDmortality observed in Denmark where TFA intake has been reduced
from 6g per day to 1g per day [12].
These results have major implications for both policy and future research. The policy impli-
cations include 1) significant health benefits to the UK population might be predicted if indus-
trial TFA intake was reduced across the UK population; 2) such reductions in trans fats intake
might also be predicted to substantially reduce existing health inequalities amongst CHD
patients within the UK, an issue that has failed to be comprehensively addressed over the past
two decades despite being repeatedly highlighted as a priority. The research implications
include the IMPACTTFA model demonstrating the utility of modelling primary prevention
Fig 5. Life Years Gained (LYGs) per year, with a trans-fats daily energy intake of 0.5% across all socio-economic circumstance (SEC) quintiles
modelling unequal intake of trans fatty acids across socio-economic circumstance quintiles. LYGs by age, gender and socio-economic circumstance.
Data source: Hospital Episode Statistics.
doi:10.1371/journal.pone.0132524.g005
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strategies to analyse potential health benefits across the UK population. This model could be
further developed to contain an economic cost-benefit analysis of such potential policies, whilst
also comparing the health and economic costs and benefits of different population wide poli-
cies. Further, a longer term effect of such policies upon community prevalence could be mod-
elled using a Markov approach.
This modelling study has several strengths, modelling using large data sets which cover the
entire adult population of 35 million. Similarly, data quality is generally very good. [16,17,26,
32,33] This is the first study to quantify the effects upon the UK population of a population
wide reduction in TFA intake, and importantly the subsequent effect of such policies upon the
health inequalities seen in CHDmortality and the underlying burden. This provides quantita-
tive data demonstrating the potential strength of population level approaches to tackling CHD
inequalities; a challenge that has made very little progress over the past two decades, despite
being highlighted as a priority. The datasets used are representative of the socio-economic distri-
bution of the English andWelsh population, and using such a large dataset allows relatively pre-
cise estimates of such policies, allowing conclusions to be drawn to better inform policy makers.
This study also has limitations. We used an area level categorisation of SEC (IMD). This
may therefore be sub-optimal for analysing trends within individuals. However, area depriva-
tion measures generally correlate well with measures of individual socioeconomic position in
the UK [32]. The age and sex mortality reductions for given levels of TFA reductions were
taken from the study by O’Flaherty et al [10]. However the value for the 85+ age group was
extrapolated using the reducing mortality reduction figures from the younger age groups. Simi-
larly, the mortality reduction for a 0.25% reduction in trans fat intake was estimated using lin-
ear extrapolation. The mortality reductions themselves assumed the same age gradients as
cholesterol and similarity between sexes. In addition, the model assumes the effects of the
reductions in trans fats intake to be almost instantaneous, whilst this model does not account
for how such a reduction, or ban would be implemented. Future work could model and com-
pare various implementation strategies. Further we recognise that upon eliminating TFA, a
substitute fat may be used in its place, itself carrying a residual, albeit much lower, CHD risk.
We did not formally account for any substitutional effect. Furthermore, we model given reduc-
tions in total TFA intake, whereby the majority of the reduction would derive from industrial
TFA. We assumed that elimination of ruminant TFA would not be feasible. Moreover, current
evidence is insufficient to quantify the effect upon CHD risk of reductions in specifically, rumi-
nant TFA.
Our model uses health and TFA intake data from 2007. However, latest National Diet and
Nutrition Survey data suggests that the mean TFA intake has fallen from 1.3% to 0.8% [34].
This suggests that the more modest modelled scenario of a reduction of TFA intake by 0.5% of
daily energy, would be more applicable, however, this more modest reduction, could still yield
significant health gains, and perhaps more importantly, have a substantial impact upon exist-
ing health inequalities within CHD. This further highlights the importance of attaining the
lowest TFA intake possible, thus continuing successful reductions over the past decade.
CHD treatment uptake has been shown to be equitable across SEC quintiles [15], however,
median survival was not stratified by SEC quintile for patients with CHD. This may have there-
fore underestimated the true socio-economic gradient in median survival. Furthermore, when
modelling the effect upon resulting patient numbers and resulting hospital admission, we
assumed no future decline in case fatality. This is clearly a conservative estimate when model-
ling a 2030 scenario. The real effects upon the underlying CHD burden are thus likely to be
larger than those estimated here. The hospital admissions numbers reported as baseline, using
diverse data sources may still be an underestimate by failing to capture all readmissions during
the same calendar year. This would in turn underestimate the estimated benefits.
Quantifying the Socio-Economic Benefits of Reducing Trans Fat
PLOS ONE | DOI:10.1371/journal.pone.0132524 August 6, 2015 13 / 16
Conclusions
These results provide quantitative data to better inform policy makers. Despite recent substan-
tial reductions, CHD remains a leading cause of mortality and morbidity. It generates a health-
care and economic burden on the increasingly strained UK clinical services. Past efforts to
reduce CHD inequalities across socio-economic circumstance quintiles have been unreward-
ing. In contrast, these results demonstrate that potentially large reductions in CHDmortality,
admissions and inequalities might be achieved by any UK reduction in industrial TFA intake.
Such population based prevention policies currently remain underused, generating an avoid-
able and unequal burden on the health services, and on society.
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